JP2003516325A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003516325A5 JP2003516325A5 JP2001541001A JP2001541001A JP2003516325A5 JP 2003516325 A5 JP2003516325 A5 JP 2003516325A5 JP 2001541001 A JP2001541001 A JP 2001541001A JP 2001541001 A JP2001541001 A JP 2001541001A JP 2003516325 A5 JP2003516325 A5 JP 2003516325A5
- Authority
- JP
- Japan
- Prior art keywords
- epilepsy
- stroke
- group
- nervous system
- central nervous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000124008 Mammalia Species 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/454,136 US6605597B1 (en) | 1999-12-03 | 1999-12-03 | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| US09/454,136 | 1999-12-03 | ||
| PCT/US2000/032721 WO2001040246A1 (en) | 1999-12-03 | 2000-12-01 | Partial or full a1 agonists - n6 heterocyclic 5'-thio substituted adenosine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003516325A JP2003516325A (ja) | 2003-05-13 |
| JP2003516325A5 true JP2003516325A5 (enExample) | 2007-10-11 |
| JP4021195B2 JP4021195B2 (ja) | 2007-12-12 |
Family
ID=23803455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001541001A Expired - Fee Related JP4021195B2 (ja) | 1999-12-03 | 2000-12-01 | 部分もしくは完全ａ１アゴニスト：ｎ６複素環式５′−チオ置換アデノシン誘導体 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US6605597B1 (enExample) |
| EP (1) | EP1233973B1 (enExample) |
| JP (1) | JP4021195B2 (enExample) |
| KR (1) | KR100484988B1 (enExample) |
| CN (1) | CN1152042C (enExample) |
| AR (1) | AR029199A1 (enExample) |
| AT (1) | ATE254133T1 (enExample) |
| AU (3) | AU4138701A (enExample) |
| BR (1) | BR0016126A (enExample) |
| CA (1) | CA2389264C (enExample) |
| CZ (1) | CZ20013705A3 (enExample) |
| DE (1) | DE60006576T2 (enExample) |
| DK (1) | DK1233973T3 (enExample) |
| ES (1) | ES2208437T3 (enExample) |
| HK (1) | HK1047941A1 (enExample) |
| HU (1) | HUP0500455A2 (enExample) |
| IL (1) | IL145903A (enExample) |
| MX (1) | MXPA01011113A (enExample) |
| NO (1) | NO20015373L (enExample) |
| NZ (1) | NZ514777A (enExample) |
| PT (1) | PT1233973E (enExample) |
| TR (2) | TR200301971T4 (enExample) |
| TW (1) | TWI249536B (enExample) |
| WO (2) | WO2001040243A2 (enExample) |
| ZA (1) | ZA200204380B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
| US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| WO2001062979A2 (en) | 2000-02-23 | 2001-08-30 | Cv Therapeutics, Inc. | Dentification of partial agonists of the a2a adenosine receptor |
| GB2372741A (en) * | 2001-03-03 | 2002-09-04 | Univ Leiden | C2,8-Disubstituted adenosine derivatives and their different uses |
| GB2372742A (en) * | 2001-03-03 | 2002-09-04 | Univ Leiden | C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses |
| US7157440B2 (en) | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| US7713946B2 (en) | 2002-07-11 | 2010-05-11 | Cv Therapeutics, Inc. | Partial and full agonists A1 adenosine receptors |
| US6946449B2 (en) | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| US7144871B2 (en) * | 2002-02-19 | 2006-12-05 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| CA2482928A1 (en) * | 2002-04-18 | 2003-10-30 | Cv Therapeutics, Inc. | Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside |
| US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
| US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
| AU2003259264A1 (en) * | 2002-07-29 | 2004-02-16 | Cv Therapeutics, Inc. | Myocardial perfusion imaging using a2a receptor agonists |
| EP1590359A2 (en) | 2003-02-03 | 2005-11-02 | CV Therapeutics Inc. | PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS |
| EP1685135B1 (en) | 2003-10-21 | 2010-05-26 | Inspire Pharmaceuticals, Inc. | TETRAHYDRO-FURO[3,4-d]DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION |
| US7335648B2 (en) | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
| US7749981B2 (en) | 2003-10-21 | 2010-07-06 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
| WO2005039590A1 (en) | 2003-10-21 | 2005-05-06 | Inspire Pharmaceuticals, Inc. | Non-nucleotide compositions and method for treating pain |
| DK1682537T3 (da) | 2003-11-05 | 2012-07-09 | Sarcode Bioscience Inc | Modulatorer af celleadhæsion |
| CA2583185A1 (en) * | 2004-10-20 | 2006-04-27 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists |
| US7932376B2 (en) | 2005-05-05 | 2011-04-26 | Inspire Pharmaceuticals, Inc. | Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation |
| EP2444079B1 (en) | 2005-05-17 | 2016-11-30 | SARcode Bioscience Inc. | Compositions and Methods for Treatment of Eye Disorders |
| NZ568392A (en) * | 2005-11-30 | 2011-07-29 | Inotek Pharmaceuticals Corp | Purine derivatives and methods of use thereof |
| CA2640089C (en) | 2006-02-03 | 2013-07-23 | Cv Therapeutics, Inc. | Process for preparing an a2a-adenosine receptor agonist and its polymorphs |
| EP2021350B1 (en) | 2006-03-21 | 2016-12-21 | Rheinische Friedrich-Wilhelms-Universität Bonn | Phosphorylated a2a receptor agonists |
| US20070299089A1 (en) * | 2006-06-22 | 2007-12-27 | Cv Therapeutics, Inc. | Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia |
| US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
| WO2008028140A1 (en) * | 2006-09-01 | 2008-03-06 | Cv Therapeutics, Inc. | Methods and compositions for increasing patient tolerability during myocardial imaging methods |
| JP2011502101A (ja) * | 2006-09-29 | 2011-01-20 | ギリアード・パロ・アルト・インコーポレイテッド | 肺疾患の病歴を有する患者における心筋画像化法 |
| JP2010515081A (ja) * | 2007-01-03 | 2010-05-06 | ギリアード・パロ・アルト・インコーポレイテッド | 心筋灌流画像化 |
| CA2702984C (en) | 2007-10-19 | 2017-04-11 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
| US20110064671A1 (en) | 2008-03-10 | 2011-03-17 | Cornell University | Modulation of blood brain barrier permeability |
| CN102056485A (zh) * | 2008-04-15 | 2011-05-11 | 萨可德公司 | 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂 |
| US20090257957A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders |
| US8080562B2 (en) * | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| CN102065893A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | Lfa-1拮抗剂向胃肠系统的递送 |
| US20100086483A1 (en) * | 2008-09-29 | 2010-04-08 | Gilead Palo Alto, Inc. | Method of multidetector computed tomagraphy |
| WO2011050175A1 (en) | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| CN101934559B (zh) * | 2010-08-12 | 2013-04-17 | 中国电子科技集团公司第四十五研究所 | 具有压力调节机构的砂浆供给装置 |
| WO2014018748A1 (en) | 2012-07-25 | 2014-01-30 | Sarcode Bioscience Inc. | Lfa-1 inhibitor and polymorph thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4373097A (en) | 1981-04-27 | 1983-02-08 | Bioresearch S.R.L. | Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| CN1065529C (zh) * | 1994-06-09 | 2001-05-09 | 爱斯制药株式会社 | 4－喹啉酮衍生物及其盐 |
| US5789416B1 (en) * | 1996-08-27 | 1999-10-05 | Cv Therapeutics Inc | N6 mono heterocyclic substituted adenosine derivatives |
| GB9723590D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| GB9723566D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| US6258793B1 (en) * | 1999-12-03 | 2001-07-10 | Cv Therapeutics, Inc. | N6 heterocyclic 5′ modified adenosine derivatives |
| US6294522B1 (en) * | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
-
1999
- 1999-12-03 US US09/454,136 patent/US6605597B1/en not_active Expired - Fee Related
-
2000
- 2000-11-30 AU AU41387/01A patent/AU4138701A/en not_active Abandoned
- 2000-11-30 WO PCT/US2000/042509 patent/WO2001040243A2/en not_active Ceased
- 2000-12-01 ES ES00980919T patent/ES2208437T3/es not_active Expired - Lifetime
- 2000-12-01 WO PCT/US2000/032721 patent/WO2001040246A1/en not_active Ceased
- 2000-12-01 EP EP00980919A patent/EP1233973B1/en not_active Expired - Lifetime
- 2000-12-01 KR KR10-2002-7007097A patent/KR100484988B1/ko not_active Expired - Fee Related
- 2000-12-01 HK HK02109274.6A patent/HK1047941A1/zh unknown
- 2000-12-01 CA CA002389264A patent/CA2389264C/en not_active Expired - Fee Related
- 2000-12-01 TR TR2003/01971T patent/TR200301971T4/xx unknown
- 2000-12-01 AR ARP000106398A patent/AR029199A1/es unknown
- 2000-12-01 CZ CZ20013705A patent/CZ20013705A3/cs unknown
- 2000-12-01 PT PT00980919T patent/PT1233973E/pt unknown
- 2000-12-01 DE DE60006576T patent/DE60006576T2/de not_active Expired - Lifetime
- 2000-12-01 DK DK00980919T patent/DK1233973T3/da active
- 2000-12-01 AT AT00980919T patent/ATE254133T1/de not_active IP Right Cessation
- 2000-12-01 AU AU18117/01A patent/AU1811701A/en not_active Abandoned
- 2000-12-01 HU HU0500455A patent/HUP0500455A2/hu unknown
- 2000-12-01 JP JP2001541001A patent/JP4021195B2/ja not_active Expired - Fee Related
- 2000-12-01 MX MXPA01011113A patent/MXPA01011113A/es active IP Right Grant
- 2000-12-01 CN CNB008139334A patent/CN1152042C/zh not_active Expired - Fee Related
- 2000-12-01 BR BR0016126-8A patent/BR0016126A/pt not_active Application Discontinuation
- 2000-12-01 TR TR2001/03129T patent/TR200103129T2/xx unknown
- 2000-12-01 NZ NZ514777A patent/NZ514777A/xx active Application Filing
- 2000-12-02 TW TW089125680A patent/TWI249536B/zh active
-
2001
- 2001-10-11 IL IL145903A patent/IL145903A/en not_active IP Right Cessation
- 2001-10-12 AU AU79383/01A patent/AU761029B2/en not_active Ceased
- 2001-11-01 US US09/980,533 patent/US20050054605A1/en not_active Abandoned
- 2001-11-02 NO NO20015373A patent/NO20015373L/no not_active Application Discontinuation
-
2002
- 2002-05-31 ZA ZA200204380A patent/ZA200204380B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003516325A5 (enExample) | ||
| WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| CA2375908A1 (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
| CA2366268A1 (en) | Pharmaceutical compositions for cns and other disorders | |
| JP2002502871A5 (enExample) | ||
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| JP2005532372A5 (enExample) | ||
| JP2002523452A5 (enExample) | ||
| JP2004525194A5 (enExample) | ||
| CA2285407A1 (en) | Dosage forms comprising separate portions of r- and s-enantiomers | |
| CA2364718A1 (en) | Monoamine reuptake inhibitors for treatment of cns disorders | |
| WO2002058620A3 (es) | Composiciones farmaceuticas que contienen un inhibidor de cox-ii y un relajante muscular | |
| BG108131A (en) | Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders | |
| HUP0302333A3 (en) | The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders | |
| JP2022153638A5 (enExample) | ||
| Bacsik et al. | Toxic systemic reactions of bupivacaine and etidocaine | |
| EP1440689A3 (en) | Treatment of neurotic disorders | |
| JP2001513504A5 (enExample) | ||
| CA2433833A1 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
| HUP0301578A3 (en) | Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | |
| EE05174B1 (et) | Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nhtud hulgiskleroosi ja teiste meliinikaotusega seotud haiguste raviks | |
| JP2005527477A5 (enExample) | ||
| JP2003522147A5 (enExample) | ||
| JP2003523397A5 (enExample) | ||
| JPH10237071A5 (enExample) |